Bendamustine and rituximab is well‐tolerated and efficient in the treatment of indolent non‐Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study

Abstract Bendamustine and rituximab (BR) is a preferred first‐line therapy for indolent non‐Hodgkin's lymphoma (iNHL) and mantle cell lymphoma (MCL); however, few reports on BR performance in elderly patients are available to date. We compared safety and efficacy of BR in patients ≥70 years (elderly) vs <70 years (younger) treated at our institution. Among 201 patients, 113 were elderly (median age: 77 years), including 38 patients ≥80 years, and 88 were younger (median age: 62 years). Elderly patients had more bone marrow involvement by lymphoma, anemia, ECOG status 3 and high‐risk disease follicular lymphoma ( P < .05 for all). Fifty‐four percent of elderly received full dose of bendamustine vs 79.5% of younger patients. More elderly patients (54%) vs younger (43.2%) experienced treatment delay. Less elderly proceeded to rituximab maintenance. Overall, the number of adverse events per patient and transformed B‐Cell lymphoma/secondary malignancies were similar between groups. Elderly patients had less febrile neutropenia, rituximab‐associated infusion reactions, but more herpes zoster reactivation. There were more deaths in the elderly (37.2%) vs younger (10.2%) groups ( P < .001), mainly due to non‐lymphoma‐related causes. With median follow‐up of 42 months [4.0‐97.0] disease‐free survival for the elderly was similar to younger patients. There was no difference between patients <80 and ≥80 years ( P = .274). In conclusion, the real‐world elderly patients have more advanced disease and higher ECOG status. BR is well‐tolerated; elderly patients had lower incidence of febrile neutropenia. Dose reduction and treatment delays are common, but BR efficacy was not affected even in very old patients (≥80 years).